Non-invasive grading of astrocytic tumours from the relative contents of myo-inositol and glycine measured by in vivo MRS.

MRI and MRS are established methodologies for evaluating intracranial lesions. One MR spectral feature suggested for in vivo grading of astrocytic tumours is the apparent myo-lnositol (ml) intensity (ca 3.55 ppm) at short echo times, although glycine (gly) may also contribute in vivo to this resonance. The purpose of this study was to quantitatively evaluate the ml + gly contribution to the recorded spectral pattern in vivo and correlate it with in vitro data obtained from perchloric acid extraction of tumour biopsies. Patient spectra (n = 95) at 1.5T at short (20-31 ms) and long (135-136 ms) echo times were obtained from the INTERPRET MRS database (http://gabrmn.uab.eslinterpretvalidateddbl). Phantom spectra were acquired with a comparable protocol. Spectra were automatically processed and the ratios of the (ml + gly) to Cr peak heights ((ml + gly)/Cr) calculated. Perchloric acid extracts of brain tumour biopsies were analysed by high-resolution NMR at 9.4T. The ratio (ml + gly)/Cr decreased significantly with astrocytic grade in vivo between low-grade astrocytoma (A2) and glioblastoma multiforme (GBM). In vitro results displayed a somewhat different tendency, with anaplastic astrocytomas having significantly higher (ml + gly)/Cr than A2 and GBM. The discrepancy between in vivo and in vitro data suggests that the NMR visibility of glycine in glial brain tumours is restricted in vivo.

[1]  Carles Arús,et al.  Proton magnetic resonance spectroscopy (1H MRS) of human brain tumours: assessment of differences between tumour types and its applicability in brain tumour categorization , 2003, European Radiology.

[2]  Ying Lu,et al.  Survival analysis in patients with glioblastoma multiforme: Predictive value of choline‐to‐n‐acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume , 2004, Journal of magnetic resonance imaging : JMRI.

[3]  Margarida Julià-Sapé,et al.  The INTERPRET Decision-Support System version 3.0 for evaluation of Magnetic Resonance Spectroscopy data from human brain tumours and other abnormal brain masses , 2010, BMC Bioinformatics.

[4]  Glyn Johnson,et al.  Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. , 2003, AJNR. American journal of neuroradiology.

[5]  M. Chamberlain,et al.  Practical guidelines for the treatment of malignant gliomas. , 1998, The Western journal of medicine.

[6]  G Friedmann,et al.  Human brain tumors: spectral patterns detected with localized H-1 MR spectroscopy. , 1992, Radiology.

[7]  M. Fava,et al.  Oral glycine administration increases brain glycine/creatine ratios in men: A proton magnetic resonance spectroscopy study , 2009, Psychiatry Research: Neuroimaging.

[8]  Sylvie Grand,et al.  A new approach for analyzing proton magnetic resonance spectroscopic images of brain tumors: nosologic images , 2000, Nature Medicine.

[9]  Bernardo Celda,et al.  1 H and 13 C HR-MAS spectroscopy of intact biopsy samples ex vivo and in vivo 1 H MRS study of human high grade gliomas , 2004 .

[10]  J. Frahm,et al.  Localized proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites , 1989, Magnetic resonance in medicine.

[11]  I. Campbell,et al.  Proton spin lattice relaxation time measurements at 90MHz and 270 MHz. , 1973, Biochimica et biophysica acta.

[12]  P. Renshaw,et al.  In vivo detection of brain glycine with echo‐time‐averaged 1H magnetic resonance spectroscopy at 4.0 T , 2006, Magnetic resonance in medicine.

[13]  J Hennig,et al.  Human brain tumors: assessment with in vivo proton MR spectroscopy. , 1993, Radiology.

[14]  Mathias Hoehn,et al.  Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation , 2005, NMR in biomedicine.

[15]  B. Bobek-Billewicz,et al.  Measurement of glycine in a brain and brain tumors by means of 1H MRS. , 2010, Folia neuropathologica.

[16]  A. Bassols,et al.  Assignment of the 2.03 ppm resonance in in vivo 1H MRS of human brain tumour cystic fluid: contribution of macromolecules , 2004, Magnetic Resonance Materials in Physics, Biology and Medicine.

[17]  Sabine Van Huffel,et al.  The effect of combining two echo times in automatic brain tumor classification by MRS , 2008, NMR in biomedicine.

[18]  M. Julià-Sapé,et al.  A Multi-Centre, Web-Accessible and Quality Control-Checked Database of in vivo MR Spectra of Brain Tumour Patients , 2006, Magnetic Resonance Materials in Physics, Biology and Medicine.

[19]  S Cerdán,et al.  Nonhistological diagnosis of human cerebral tumors by 1H magnetic resonance spectroscopy and amino acid analysis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  J K Smith,et al.  Correlation of myo-inositol levels and grading of cerebral astrocytomas. , 2000, AJNR. American journal of neuroradiology.

[21]  P. Allen,et al.  Strategy for the spectral filtering of myo‐inositol and other strongly coupled spins , 2004, Magnetic resonance in medicine.

[22]  Y. Kinoshita,et al.  Absolute concentrations of metabolites in human brain tumors using in vitro proton magnetic resonance spectroscopy , 1997, NMR in biomedicine.

[23]  J Hennig,et al.  Coupling effects in volume selective 1H spectroscopy of major brain metabolites , 1991, Magnetic resonance in medicine.

[24]  J. Lemasters,et al.  Glycine blocks opening of a death channel in cultured hepatic sinusoidal endothelial cells during chemical hypoxia , 2001, Cell Death and Differentiation.

[25]  A R Tate,et al.  Magnetic resonance spectroscopy of brain hemangiopericytomas: high myoinositol concentrations and discrimination from meningiomas. , 2001, Journal of neurosurgery.

[26]  D K Pearl,et al.  Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas , 1997, Cancer.

[27]  Brian D. Ross,et al.  Magnetic Resonance Spectroscopy Diagnosis of Neurological Diseases , 1999 .

[28]  M. Law,et al.  Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications. , 2009, Clinical radiology.

[29]  Wietske van der Zwaag,et al.  In vivo measurement of glycine with short echo-time 1H MRS in human brain at 7 T , 2009, Magnetic Resonance Materials in Physics, Biology and Medicine.

[30]  F. Podo,et al.  Differentiation of glioblastoma multiforme from astrocytomas by in vitro 1H MRS analysis of human brain tumors. , 1996, Anticancer research.

[31]  Marinette van der Graaf,et al.  In vivo magnetic resonance spectroscopy: basic methodology and clinical applications , 2009, European Biophysics Journal.

[32]  G. Sutherland,et al.  High‐Resolution 1H NMR spectroscopy studies of extracts of human cerebral neoplasms , 1992, Magnetic resonance in medicine.

[33]  Franklyn A Howe,et al.  Combined use of neuroradiology and 1H‐MR spectroscopy may provide an intervention limiting diagnosis of glioblastoma multiforme , 2010, Journal of magnetic resonance imaging : JMRI.

[34]  S. Kalra,et al.  Measurement of glycine in human brain by triple refocusing 1H‐MRS in vivo at 3.0T , 2008, Magnetic resonance in medicine.

[35]  A. W. Simonetti,et al.  Development of a decision support system for diagnosis and grading of brain tumours using in vivo magnetic resonance single voxel spectra , 2006, NMR in biomedicine.

[36]  R. Agati,et al.  Identification of mobile lipids in human cancer tissues by ex vivo diffusion edited HR-MAS MRS. , 2009, Oncology reports.

[37]  Paul S Mischel,et al.  Molecular Analysis of Glioblastoma: Pathway Profiling and Its Implications for Patient Therapy , 2003, Cancer biology & therapy.

[38]  M. Mirabet,et al.  Glycine protects cardiomyocytes against lethal reoxygenation injury by inhibiting mitochondrial permeability transition , 2004, The Journal of physiology.

[39]  Franklyn A Howe,et al.  Ex-vivo HRMAS of adult brain tumours: metabolite quantification and assignment of tumour biomarkers , 2010, Molecular Cancer.

[40]  J. Weinberg,et al.  Glycine Protection of PC-12 Cells Against Injury by ATP-Depletion , 2003, Neurochemical Research.

[41]  Margarida Julià-Sapé,et al.  Brain tumor classification by proton MR spectroscopy: comparison of diagnostic accuracy at short and long TE. , 2004, AJNR. American journal of neuroradiology.

[42]  B. Stewart,et al.  World Cancer Report , 2003 .

[43]  Irina Mader,et al.  Proton chemical shift imaging, metabolic maps, and single voxel spectroscopy of glial brain tumors , 1996, Magnetic Resonance Materials in Physics, Biology and Medicine.

[44]  M. Décorps,et al.  In Vivo, Ex Vivo, and In Vitro One‐ and Two‐Dimensional Nuclear Magnetic Resonance Spectroscopy of an Intracerebral Glioma in Rat Brain: Assignment of Resonances , 1994, Journal of neurochemistry.

[45]  Margarida Julià-Sapé,et al.  MRS quality assessment in a multicentre study on MRS‐based classification of brain tumours , 2008, NMR in biomedicine.

[46]  Pieter Wesseling,et al.  Comparison between neuroimaging classifications and histopathological diagnoses using an international multicenter brain tumor magnetic resonance imaging database. , 2006, Journal of neurosurgery.

[47]  H. Lanfermann,et al.  1H MR spectroscopic imaging with short and long echo time to discriminate glycine in glial tumours , 2009, Magnetic Resonance Materials in Physics, Biology and Medicine.